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ABSTRACT Pre-mRNA splicing requires a large number
of RNA-binding proteins that have one or more RNA-
recognition motifs (RRMs). Among these is the SR protein
family, whose members are essential for splicing and are able
to commit pre-mRNAs to the splicing pathway with overlap-
ping but distinct substrate specificity. Some SR proteins, such
as SC35, contain an N-terminal RRM and a C-terminal
arginineyserine-rich (RS) domain, whereas others, such as
SF2yASF, also contain a second, atypical RRM. Although
both the RRMs and the RS domain of SR proteins are required
for constitutive splicing, it is unclear which domain(s) defines
their substrate specificity, and whether two RRMs in a given
SR protein function independently or act coordinately. Using
domain swaps between SC35 and SF2yASF and a functional
commitment assay, we demonstrate that individual domains
are functional modules, RS domains are interchangeable, and
substrate specificity is defined by the RRMs. The atypical
RRM of SF2yASF does not appear to function alone in
splicing, but can either activate or suppress the splicing
specificity of an N-terminal RRM. Therefore, multiple RRMs
in SR proteins act coordinately to achieve a unique spectrum
of pre-mRNA substrate specificity.
Pre-mRNA splicing is a critical step in the posttranscriptional
regulation of gene expression and requires both small nuclear
ribonucleoprotein particles (snRNPs) and non-snRNP factors.
These factors assemble on pre-mRNA into a large complex
known as a spliceosome, in which splicing takes place (for
review, see ref. 1). A family of arginineyserine-rich non-snRNP
splicing factors called SR proteins mediate various steps of
spliceosomal assembly (for reviews, see refs. 2 and 3). In
constitutive splicing, binding of SR proteins is sufficient to
commit pre-mRNA to the splicing pathway (4), probably by
facilitating U1 snRNP binding to a functional 59 splice site (5),
stabilizing complex assembly at the 39 splice site (6), and
bridging complexes assembled at the 59 and 39 splice sites
(7–9). Additionally, SR proteins can modulate splice site
selection, which is consistent with their involvement in early
steps of splice site recognition (for review, see ref. 10).
SR proteins are essential splicing factors, but they have
overlapping functions, at least in vitro, because all SR proteins
can complement the splicing-deficient S100 cytoplasmic ex-
tract (11, 12). However, individual SR proteins clearly perform
distinct activities in splicing different pre-mRNA substrates,
and bind to different RNA sequence elements (for reviews, see
refs. 2 and 3). It has been shown that the SR protein B52y
SRp55 is essential for Drosophila development, although splic-
ing of a number of transcripts examined in mutant larvae was
not affected, indicating that these transcripts are not depen-
dent on B52ySRp55 (13, 14). More recently, another SR
protein, SF2yASF, was analyzed by targeted gene disruption in
a chicken B-cell line and shown to be essential for cell viability,
indicating that this SR protein also has at least one nonre-
dundant function in vivo (15).
Although SR proteins have distinct functions, little is known
about the structural basis of their observed splicing specificity.
The family of SR proteins is characterized by the presence of
an N-terminal RNA recognition motif (RRM) and a C-
terminal arginineyserine-rich (RS) domain. A subset of SR
protein family members have a unique central domain sepa-
rating the N-terminal canonical RRM and the C-terminal RS
domain that is common to all family members. This central
domain is an atypical RRM that lacks conserved residues
present in the RNP2- and RNP1-submotifs of canonical RRMs
(for review, see ref. 16). RNA-binding studies of SF2yASF
revealed that each of its RRMs can bind to RNA, but two
RRMs together seem to bind better (17, 18) and with distinct
binding specificity (19). On the other hand, in other RNA-
binding proteins containing multiple RRMs, such as the
U1-associated A (U1A) protein, the N-terminal RRM appears
to bind specifically to U1 snRNA (20, 21), whereas the second
RRM may independently bind to pre-mRNA sequences (22).
In this paper, we addressed the specificity and cooperation
of individual domains in SR proteins using a functional splicing
commitment assay. Our results demonstrate that the RS
domains are functionally interchangeable and that splicing
specificity is determined by the RRMs in SR proteins. Most
interestingly, we found that the second, atypical RRM in
SF2yASF appears to be inactive in splicing as the sole RRM,
but is able to suppress or activate the splicing specificity of an
adjacent canonical RRM.
MATERIALS AND METHODS
Construction of Chimeric SC35 and SF2yASF Proteins.The
SC35 coding sequence (23) was subcloned from pSP73-SC35
as a NarI-PvuI fragment into PharMingen’s pAcG2T baculo-
virus vector at the SmaI site to generate pAcG2T-SC35. The
SF2yASF coding sequence (24) was isolated from pBSK-SF2y
ASF by PCR amplification using the upstream primer F1
(59-GCCGGATCCGGAGGTGGTGTG-39), which contains a
BamHI site (underlined) and anneals to the SF2yASF coding
region corresponding to amino acids 2–6, and a downstream
primer complementary to a plasmid sequence. The amplified
cDNA was subcloned into pAcG2T at the BamHI and EcoRI
sites to produce pAcG2T-SF2yASF. Construction of individ-
ual chimeric proteins was as follows.
C1F2FRS. The SC35 RRM coding sequence was amplified
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the downstream primer C1 (CGGCTCCGAGCTCCG-
TAGCCA), which contains a SacI site (underlined) and an-
neals to the region corresponding to SC35 amino acids 113–
116. The amplified product was digested with StuI and SacI and
used to replace the StuI-SacI fragment in pBSK-SF2yASF. The
hybrid cDNA insert was isolated by digestion with NarI,
followed by filling-in with Klenow fragment, and then with
EcoRI. The fragment was subcloned into pAcG2T at the SmaI
and EcoRI sites.
F1C1FRS. The SC35 RRM cDNAwas amplified from pSP73-
SC35 using the upstream primer C2 (CTCAGAGCTCT-
GAGCTACGGCCGC), which contains a SacI site (under-
lined) and anneals to the region corresponding to SC35 amino
acids 1–5, and the downstream primer C3 (GGGGCCCG-
TAGCGCGCCATTTGC), which contains an ApaI site (un-
derlined) and anneals to SC35 amino acids 87–93. The ampli-
fied cDNA was digested with SacI and ApaI and used to
replace the SacI-ApaI fragment in pAcG2T-SF2yASF.
F1F2CRS. A cDNA encoding both RRMs of SF2yASF was
amplified from pAcG2T-SF2yASF with a pAcG2T upstream
primer and the downstream primer F2 (CCATACCTAG-
GACTTCTGGGCCCATC), which contains an AvrII site (un-
derlined) and anneals to the region corresponding to SF2yASF
amino acids 195–203. The cDNA was subcloned into pAcG2T-
SC35 using BamHI and AvrII.
C1F2CRS. The cDNA encoding RRM2 of SF2yASF was
amplified from pAcG2T-SF2yASF using the upstream primer
F3 (CCCCACCTAGGCGGTCTGAAAC), which anneals to
the region corresponding to SF2yASF amino acids 114–121,
and the downstream primer F2, both of which contain an AvrII
site (underlined). The cDNA was subcloned into pAcG2T-
SC35 at the AvrII site.
C1F1CRS. The SF2yASFRRM1 coding region was amplified
from pBSK-SF2yASF using the upstream primer F4 (GTCAC-
CCCTAGGTCGGGAGGT), which anneals to the region
corresponding to SF2yASF amino acids 1–4, and the down-
stream primer F5 (ACGGCCTGTCCTAGGGCCGCT),
which anneals to the region corresponding to SF2yASF amino
acids 121–127. The PCR product was digested with AvrII at the
underlined sites in both primer sequences and the cDNA was
inserted into the AvrII site in pAcG2T-SC35.
F2FRS. The upstream primer F6 (CGGTCTGGATCCA-
GAGTGGTTG), which contains a BamHI site (underlined)
and anneals to the region corresponding SF2yASF amino acids
148–154, and a downstream primer for pBSK sequence were
used to amplify the coding region for RRM2 and the RS
domain of SF2yASF from pBSK-SF2yASF. The PCR product
was digested with BamHI and EcoRI and the DNA was
inserted into pAcG2T at the corresponding sites.
F1FRS. The cDNA encoding the SF2yASF RS domain was
amplified using the upstream primer F7 (CCCAGAGCTC-
CAAGTTATGG), which contains a SacI site (underlined) and
anneals to the region corresponding to SF2yASF amino acids
197–203, and a downstream primer complementary to a
plasmid sequence in pAcG2T-SF2yASF. The cDNA product
was digested with SacI and EcoRI and used to replace the
SacI-EcoRI fragment in pAcG2T-SF2yASF.
F1CRS. The cDNA encoding the SC35 RS domain was
amplified using primer C4 (TGGCTACGGAGCTCGGAG),
which contains a SacI site (underlined) and anneals to the
region corresponding to SC35 amino acids 113–119, and a
downstream primer complementary to a plasmid sequence in
pAcG2T-SC35. The amplified product was digested with SacI
and EcoRI and used to replace the SacI-EcoRI fragment in
pAcG2T-SF2yASF.
Baculovirus Expression of Recombinant Proteins. All con-
structs were sequenced prior to transfection. The PharMingen
Baculogold System was used to express wild-type and chimeric
proteins in Sf9 cells. Following initial transfection, the viral
titer was increased through three rounds of amplification over
16 days. Final protein production was performed using 1–2 ml
of virus stock (about 13 108 pfuyml) to infect 23 107 Sf9 cells
in one 150-mm culture dish. In general, 10 dishes were infected
with each construct. Infected cells were harvested, resus-
pended in 10 ml of PBS with 1% Triton X-100, and lysed by
sonication. Cellular debris was removed by centrifugation for
30 min at 35,000 rpm in a Beckman SW41 rotor, and the
supernatant was added to Pharmacia Sepharose 4B glutathi-
one beads equilibrated with PBS. Proteins were allowed to
bind at 48C for 1 hr to overnight. Following three washes with
PBS, proteins were eluted with 15 mM reduced glutathione in
BC100 buffer (100 mM KCly20 mM HepeszHCl, pH 7.6y10%
glycerol). The protein concentration was normalized to about
0.1 mgyml by Coomassie blue staining after SDSyPAGE, using
BSA as a standard. The samples were aliquoted and stored at
2808C until they were used.
Splicing Commitment Assay. The assay was carried out as
described (4). Briefly, individual splicing mixtures were set up
containing 0.2 mg of each SR protein (the volume was adjusted
to 12 ml by adding BC100), 2 ml labeled pre-mRNA substrate
(105 cpm, 0.05 pmol), 1 ml ATP (12.5 mM), 1 ml phosphocre-
atine (0.5 M, Sigma), 1 ml MgCl2 (80 mM), 0.25 ml DTT (0.2
M), 0.25 ml RNAsin (40 units per ml, Promega), and 2.5 ml
H2O. After incubation at 308C for 10 min, a mixture containing
3 ml nuclear extract plus 2 ml competitor RNA (1 pmolyml; the
unlabeled competitor is the 59 half of human b-globin pre-
mRNA transcribed from plasmid T7Hb linearized with XhoI
in the middle of the intron, see ref. 25) was added to each tube
and incubation was continued for 2 hr. Products of the splicing
reactions were resolved on a 6% denaturing polyacrylamide
gel. Quantitation was obtained using a SCAN ANALYSIS pro-
gram, and splicing efficiency was expressed as the ratio of
spliced mRNAyunspliced pre-mRNA.
RESULTS
Construction and Expression of SF2yASF and SC35 Chi-
meric Proteins. We chose two SR proteins, SF2yASF (which
has the additional RRM) and SC35 (which lacks it), as models
to investigate the specificity contributed by individual domains
of SR proteins in constitutive splicing. The splicing activity of
wild-type and chimeric proteins was measured by a commit-
ment assay, in which a labeled pre-mRNA is preincubated with
a specific SR protein, followed by addition of a nuclear extract
whose ability to splice by itself is blocked by excess competitor
RNA (4). We have previously shown that SC35 commits
human b-globin pre-mRNA to splicing more efficiently than
SF2yASF, whereas SF2yASF, but not SC35, commits HIV tat
pre-mRNA to splicing (ref. 4; see also Fig. 2). To investigate
which domains of SF2yASF contribute to tat pre-mRNA
splicing, we constructed and expressed a series of chimeric
glutathione S-transferase (GST)-fusion SR proteins (Fig. 1).
GST-fusion proteins were purified in a single step from
baculovirus-infected cells (Fig. 1D). To ensure that the GST-
fusion proteins function in splicing with the same specificity as
authentic proteins, we compared untagged SF2yASF and
SC35 with the GST-fusion proteins in splicing of both human
b-globin and tat pre-mRNA. The results confirmed that the
GST-fusion proteins have the same substrate specificity as
native SR proteins (A.M. et al., unpublished data).
RRMs, but Not RS Domains, Determine Splicing Specific-
ity. To determine whether the splicing specificity of SF2yASF
with the tat pre-mRNA is defined by its RRMs or by its RS
domain, we first substituted individual domains of SF2yASF
with the corresponding domains of SC35 to generate C1F2FRS,
F1C1FRS, and F1F2CRS (Fig. 1B). All three chimeric GST-
fusion proteins were active in committing human b-globin
pre-mRNA to the splicing pathway, indicating that the chi-
meric proteins fold properly to function in constitutive splicing
(Fig. 2A). In contrast, striking differences in the activities of
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the same proteins were observed in tat pre-mRNA splicing
commitment (Fig. 2B). The F1F2CRS mutant, in which the RS
domain of SF2yASF was replaced with that of SC35, was as
active as wild-type SF2yASF, suggesting that the RS domains
of SF2yASF and SC35 are functionally interchangeable, and
therefore, do not contribute to tat splicing specificity. This
result is reminiscent of the previous observation that the RS
domains from the Drosophila splicing regulators Tra and
SWAP are interchangeable in vivo (26). In contrast, replacing
the N-terminal RRM (RRM1) of SF2yASF with that of SC35
(C1F2FRS) dramatically reduced, but did not completely abol-
ish, its ability to splice the tat pre-mRNA. Replacing the
second RRM (RRM2) of SF2yASF with the RRM of SC35
(F1C1FRS), however, completely abolished tat splicing. These
findings demonstrate that both RRMs of SF2yASF contribute
to tat splicing specificity.
The Atypical RRM2 of SF2yASF Activates SC35 for tat
Splicing. To further evaluate the contributions of RRM1 and
RRM2 of SF2yASF in defining tat substrate specificity, we
constructed two additional chimeric proteins, C1F1CRS and
C1F2CRS, by inserting individual RRMs from SF2yASF into
SC35 (Fig. 1B). Both proteins were highly active in b-globin
splicing commitment (Fig. 2A). When tested with the tat
pre-mRNA, the insertion of RRM2 into SC35 conferred tat
splicing specificity more efficiently than the insertion of RRM1
(compare lanes 8 and 9 in Fig. 2B). These data suggest that the
atypical RRM2 of SF2yASF plays a major role in defining tat
pre-mRNA specificity by positively modulating an upstream
canonical RRM from either SF2yASF or SC35, although the
natural combination of RRM1 and RRM2 in wild-type SF2y
ASF results in maximal synergy for tat pre-mRNA splicing
(compare lanes 4, 8, and 9 in Fig. 2B). The results of these
functional studies are consistent with the previous observa-
tions that RRM1 and RRM2 of SF2yASF cooperate for
general binding to RNA (17, 18) and for high affinity binding
to specific splicing enhancer elements (19), similar to those
present in tat pre-mRNA (27, 28).
The Canonical RRM1 of SF2yASF Can Function in Splicing
in the Absence of the Atypical RRM2. The observation that
domains from two SR proteins can be interchanged to gener-
ate chimeric proteins that are active in both b-globin and tat
splicing commitment suggests that individual domains in SR
proteins are functional modules, which can act either inde-
pendently or cooperatively. In a number of other RNA-binding
proteins with multiple RRMs, it has been observed that
individual RRMs function independently in binding to RNA
(20–22, 29). The RRMs of SF2yASF also appear to function
independently in the formation of a ternary complex with
pre-mRNA and U1 snRNP, since either RRM1 or RRM2, in
combination with the RS domain, is sufficient to promote
binding of purified U1 snRNP to a 59 splice site (30). To extend
this observation in the context of the complete splicing reac-
tion, we deleted RRM1 or RRM2 from SF2yASF, or fused
RRM1 of SF2yASF with the RS domain of SC35, to produce
F2FRS, F1FRS, and F1CRS, respectively (Fig. 1C). As expected
from the requirement for both RRMs of SF2yASF in tat
pre-mRNA splicing, all three domain-deletion mutants were
inactive in tat splicing (Fig. 3B). We observed no activity of
F2FRS in b-globin splicing (Fig. 3A), indicating either that
RRM2 of SF2yASF cannot function alone, or that the deletion
mutant is misfolded and therefore inactive in the commitment
assay. We also tested an RS domain deletion mutant of
SF2yASF (referred to as RRMycRRM by Ca´ceres and
Krainer, see ref. 17) in the commitment assay. This mutant was
previously shown to be inactive in constitutive splicing by S100
extract complementation, but capable of affecting alternative
splice site selection in nuclear extracts (17). We detected no
activity of the mutant protein in either b-globin or tat splicing,
confirming that the RS domain is also essential for constitutive
splicing in nuclear extracts (data not shown). In contrast, both
F1FRS, and F1CRS were functional in committing b-globin
pre-mRNA to splicing (Fig. 3A). Therefore, the N-terminal
canonical RRM1 of SF2yASF can function in splicing without
the atypical RRM2, in a structural arrangement that resembles
that of authentic SC35. In this single RRM context, the RS
domains are again interchangeable between the two SR pro-
teins.
The Atypical RRM2 of SF2yASF Suppresses Its Activity in
IgM Splicing. Recently, it was observed by S100 complemen-
tation that a constitutive splicing event in a human IgM
pre-mRNA comprising exons C3 and C4 depends on SC35, but
not on SF2yASF (A.M. et al., unpublished results). Because
F1FRS and SC35, both of which consist of a single RRM joined
to an RS domain, behaved similarly in b-globin splicing, we
asked whether the lack of activity of wild-type SF2yASF in
IgM splicing was due to the suppression of IgM-specific
splicing through negative modulation by the atypical RRM2 of
SF2yASF. As shown in Fig. 4, wild-type SC35, but not SF2y
FIG. 1. Construction and expression of SF2yASF-SC35 chimeric
proteins. (A) Wild-type SF2yASF and SC35. Domains of SF2yASF
and SC35 are shown by open and shaded boxes, respectively (not to
scale). Three restriction sites shown in the wild-type constructs were
used to swap domains between the two proteins. The nomenclature is
based on the origin of each domain: F, a domain from SF2yASF; C,
a domain from SC35. RRM, RNA-recognition motif. RS, argininey
serine-rich domain. (B) Domain-swap proteins. (C) Domain-deletion
proteins. (D) Purified GST-fusion proteins resolved by 12.5% SDSy
PAGE. Molecular weight markers are indicated on the right.
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ASF, committed IgM pre-mRNA to splicing. Remarkably,
deletion of RRM2 from SF2yASF allowed commitment of
IgM pre-mRNA to splicing (F1FRS). As was seen for b-globin
and tat pre-mRNAs, the RRM2 of SF2yASF as the sole RRM
could not function in IgM splicing (F2FRS), and the RS
domains from SF2yASF and SC35 were interchangeable
(F1CRS). This experiment clearly shows that RRM2 negatively
modulates the N-terminal RRM1 of native SF2yASF to sup-
press its activity in committing IgM pre-mRNA to the splicing
pathway.
DISCUSSION
The present studies illustrate the modular nature of SR
proteins and show that, although the RS domains are essential
for constitutive splicing, they are interchangeable between
SC35 and SF2yASF for the substrates tested. These observa-
tions suggest that the RS domain of SR proteins may function
as an effector domain to activate splicing, but plays no role in
defining substrate specificity. However, in light of the phylo-
genetic conservation of RS domains in individual SR proteins
(16), and the proposed involvement of this domain in specific
protein–protein interactions (5, 8) and in regulation of splicing
or localization by phosphorylation (2, 3), individual RS do-
mains are probably not functionally equivalent in vivo, as they
may engage in specific interactions to determine the efficiency,
regulation, or localization of individual members of the SR
family of splicing factors.
Our findings on the function and cooperation of RRMs in
SR proteins determined by a functional splicing assay extend
FIG. 2. Activities of domain-swap proteins in a splicing commitment assay. (A) Human b-globin pre-mRNA (transcribed from a minigene,
pSP73–HbD6, which comprises exons G1 andG2 and intron 1) was spliced in the absence (lane 1) or the presence (lanes 2–9) of unlabeled competitor
RNA corresponding to the 59 half of the human b-globin pre-mRNA (4, 25). In each lane (from 2 to 9), 0.2 mg of the indicated protein was
preincubated with the labeled pre-mRNA, followed by the addition of 3 ml of HeLa cell nuclear extract blocked with 2 pmol of unlabeled competitor
RNA. (B) HIV tat pre-mRNA (transcribed from a minigene, pSP73-tat, which contains exons T2 and T3 and a truncated intron 1) was spliced
under the same conditions. The bands corresponding to splicing intermediates and products are indicated. p, aberrant tat pre-mRNA cleavage
product unrelated to splicing as previously described (11). Splicing efficiency is shown as the ratio of spliced to unspliced RNA underneath each
lane.
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previous structure–function studies on SF2yASF. These stud-
ies showed that a deletion within RRM2 (18) or the complete
removal of the domain (17) abolished both the in vitro splicing
and 59 splice site switching activities associated with SF2yASF.
In addition, the high-affinity consensus RNA elements se-
lected with the wild-type SF2yASF are distinct from that
selected with the RRM1 of SF2yASF alone (19). These
observations have led to the conclusion that the individual
RNA recognition motifs of SF2yASF act synergistically in
RNA binding and splicing. Our studies extend this view of
domain cooperation by showing that the SF2yASF-SC35 chi-
meric proteins are highly active in human b-globin splicing.
Thus, the RRM1 of SF2yASF need not be coupled with the
adjacent RRM2 to function as a general splicing factor. Our
observation emphasizes that the individual domains of SF2y
ASF may act independently as functional modules, which
confirms and extends previous binding studies with SF2yASF.
First, the individual RRMs of SF2yASF can each bind to RNA
(17–19). Second, either RRM1 or RRM2 of SF2yASF in
combination with its RS domain is capable of interacting with
U1 snRNP and the 59 splice site to form ternary complexes
(30). Thus, it appears that a single RRM plus an RS domain
is sufficient for 59 splice site recognition.
This finding appears to contradict previous reports that the
RRM2 of SF2yASF is required for b-globin pre-mRNA splic-
ing in a splicing-deficient S100 cytosolic extract, which contains
only trace amounts of SR proteins (17, 18). This discrepancy
may result from differences in the assay systems used (S100
extract complementation vs. commitment in nuclear extract)
or in the way recombinant proteins were obtained (his-tagged
proteins expressed in Escherichia coli vs. GST-fusions ex-
pressed in baculovirus) or both. We therefore tested our
baculovirus-expressed GST-fusion proteins by S100 comple-
mentation. All chimeric proteins (Fig. 1B) gave results iden-
tical to those (as shown in Fig. 2) obtained by the commitment
assay (A.M. et al., unpublished results), indicating that both
assays provide equivalent measures of the substrate specificity
of SR proteins. In contrast, however, we detected only a trace
amount of activity with both F1FRS and F1CRS in b-globin
splicing by S100 complementation (data not shown). There-
FIG. 3. Activities of domain-deletion mutants in the splicing commitment assay. (A) Human b-globin pre-mRNA. (B) HIV tat pre-mRNA. Each
pre-mRNA was spliced in the absence (lane 1) or presence (lanes 2–7) of unlabeled competitor RNA after preincubation under splicing conditions
with buffer control (lanes 1 and 2) or with wild-type and domain-deletion mutants (lanes 3–7), as indicated above the autoradiogram.
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fore, it appears that the discrepancy results largely from the
nature of the two assays. The commitment assay (seeMaterials
and Methods) may facilitate specific RNA–protein interactions
during preincubation of the SR protein with the pre-mRNA.
In addition, this assay employs competitor RNA-blocked
nuclear extracts, which may contain a higher concentration of
splicing factors for cooperation than the S100 extract.
Our results demonstrate that, in the case of SF2yASF, the
atypical RRM2 does not appear to function alone in splicing,
but can either positively or negatively modulate splicing activ-
ity in conjunction with a canonical N-terminal RRM1. The
mechanism for such modulation is not known and may operate
in one of the following ways. First, individual RRMs in an SR
protein may have their own RNA-binding specificity and
interact independently with distinct RNA elements in pre-
mRNA, which can lead to the stimulation or suppression of
spliceosome assembly. Although there is no experimental
evidence to support this model for SF2yASF, other RNA-
binding proteins, such as U1A, appear to function in such a
manner (22). Second, the RNA-binding properties of adjacent
RRMs may be mutually affected such that two RRMs together
select a distinct set of optimal RNA sequences present in
splicing substrates. This possibility is consistent with the
observations that the RRM2 of SF2yASF is a functional
RNA-binding domain (17, 18), but the two-RRM configura-
tion in native SF2yASF has a different RNA-binding speci-
ficity (19). Finally, RRM2 of SF2yASF may be a domain
involved in both protein–protein and protein–RNA interac-
tions, thereby modulating splicing specificity during spliceo-
some assembly. Such a mechanism has been shown to operate
for other DNA- and RNA-binding proteins. For example, in
the case of two snRNP-associated proteins (U1A and U2B”),
whereas the U1A protein can recognize U1 snRNA alone, the
U2B” protein binds specifically to U2 snRNA only in the
presence of a second protein, U2A9 (20, 21). Further studies
are required to distinguish among these possibilities.
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